Freestone Grove Partners LP Makes New Investment in Avantor, Inc. $AVTR

Freestone Grove Partners LP purchased a new stake in Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,714,884 shares of the company’s stock, valued at approximately $56,577,000. Freestone Grove Partners LP owned approximately 0.84% of Avantor as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Private Management Group Inc. raised its holdings in Avantor by 50.4% in the 4th quarter. Private Management Group Inc. now owns 2,456,859 shares of the company’s stock worth $28,156,000 after purchasing an additional 823,572 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Avantor during the 2nd quarter valued at about $800,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Avantor during the second quarter valued at about $805,000. Assenagon Asset Management S.A. increased its position in shares of Avantor by 425.0% during the second quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock valued at $5,513,000 after buying an additional 450,801 shares during the period. Finally, Brickwood Asset Management LLP raised its stake in Avantor by 6,891.9% in the fourth quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company’s stock worth $36,489,000 after buying an additional 3,138,504 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on AVTR shares. Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $13.00 target price on shares of Avantor in a research report on Thursday, July 30th. Barclays raised their target price on Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Sanford C. Bernstein initiated coverage on Avantor in a research report on Friday, June 26th. They set a “market perform” rating and a $10.50 price target on the stock. Finally, Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Avantor has a consensus rating of “Hold” and a consensus target price of $12.00.

Avantor Stock Up 0.9%

AVTR stock opened at $14.55 on Thursday. The business has a 50 day moving average of $11.92 and a 200 day moving average of $9.71. The firm has a market cap of $9.84 billion, a PE ratio of -17.32, a price-to-earnings-growth ratio of 10.88 and a beta of 0.89. Avantor, Inc. has a twelve month low of $7.26 and a twelve month high of $15.93. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02. The firm had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The company’s revenue was up .5% on a year-over-year basis. During the same period last year, the company earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts forecast that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.